YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market
YD Bio Limited (NASDAQ: YDES) has successfully completed its business combination with Breeze Holdings Acquisition Corp and commenced trading on the Nasdaq Global Market. The transaction, approved on August 14, 2025, includes a PIPE offering that, combined with trust funds, will provide over $11.5 million for future operations.
Led by Chairman Dr. Ethan Shen, YD Bio focuses on three core areas: DNA methylation-based cancer detection through partnership with EG BioMed, ophthalmology therapies developed with 3D Global Biotech, and clinical trial support services. The company's cancer detection portfolio includes a pancreatic cancer screening test and an upcoming breast cancer recurrence monitoring test, while their ophthalmology program plans to initiate trials for exosome-based treatments in 2027.
YD Bio Limited (NASDAQ: YDES) ha completato con successo la fusione con Breeze Holdings Acquisition Corp ed è iniziata la quotazione sul Nasdaq Global Market. L'operazione, approvata il 14 agosto 2025, comprende un'offerta PIPE che, insieme ai fondi del trust, fornirà oltre $11,5 milioni per le attività future.
Sotto la guida del Presidente Dr. Ethan Shen, YD Bio si concentra su tre aree principali: la rilevazione del cancro basata sulla metilazione del DNA in collaborazione con EG BioMed, le terapie oftalmologiche sviluppate con 3D Global Biotech e i servizi di supporto per studi clinici. Il portafoglio per la diagnosi oncologica include un test per lo screening del cancro al pancreas e un test per il monitoraggio delle recidive del cancro al seno in arrivo, mentre il programma oftalmologico prevede l'avvio di studi sulle terapie a base di esosomi nel 2027.
YD Bio Limited (NASDAQ: YDES) ha completado con éxito su fusión con Breeze Holdings Acquisition Corp y ha comenzado a cotizar en el Nasdaq Global Market. La transacción, aprobada el 14 de agosto de 2025, incluye una oferta PIPE que, junto con los fondos del fideicomiso, proporcionará más de $11,5 millones para operaciones futuras.
Bajo la dirección del presidente Dr. Ethan Shen, YD Bio se centra en tres áreas clave: la detección de cáncer basada en la metilación del ADN en asociación con EG BioMed, las terapias oftalmológicas desarrolladas con 3D Global Biotech y los servicios de apoyo para ensayos clínicos. Su cartera de detección oncológica incluye una prueba de cribado para cáncer de páncreas y una próxima prueba para el seguimiento de recurrencias de cáncer de mama, mientras que el programa oftalmológico planea iniciar ensayos de terapias basadas en exosomas en 2027.
YD Bio Limited (NASDAQ: YDES)는 Breeze Holdings Acquisition Corp와의 합병을 성공적으로 완료하고 나스닥 글로벌 마켓에 상장 거래를 시작했습니다. 이 거래는 2025년 8월 14일 승인되었으며, PIPE 공모와 신탁 자금을 합쳐 향후 운영을 위해 1,150만 달러 이상을 제공할 예정입니다.
회장 Dr. Ethan Shen의 지도 아래 YD Bio는 세 가지 핵심 분야에 주력합니다: EG BioMed와의 협력을 통한 DNA 메틸화 기반 암 검출, 3D Global Biotech와 개발 중인 안과 치료제, 그리고 임상시험 지원 서비스. 암 검출 포트폴리오에는 췌장암 스크리닝 검사와 곧 선보일 유방암 재발 모니터링 검사가 포함되며, 안과 프로그램은 2027년에 엑소좀 기반 치료제 임상시험을 시작할 계획입니다.
YD Bio Limited (NASDAQ: YDES) a finalisé avec succès sa fusion avec Breeze Holdings Acquisition Corp et a commencé à être cotée sur le Nasdaq Global Market. La transaction, approuvée le 14 août 2025, inclut une offre PIPE qui, combinée aux fonds du trust, fournira plus de 11,5 millions de dollars pour les opérations futures.
Sous la direction du président Dr Ethan Shen, YD Bio se concentre sur trois domaines principaux : la détection du cancer basée sur la méthylation de l'ADN en partenariat avec EG BioMed, les thérapies ophtalmologiques développées avec 3D Global Biotech, et les services de soutien aux essais cliniques. Le portefeuille de détection oncologique comprend un test de dépistage du cancer du pancréas et un test de surveillance des récidives du cancer du sein à venir, tandis que le programme ophtalmologique prévoit de lancer des essais de traitements à base d'exosomes en 2027.
YD Bio Limited (NASDAQ: YDES) hat seine Unternehmensverschmelzung mit Breeze Holdings Acquisition Corp erfolgreich abgeschlossen und den Handel am Nasdaq Global Market aufgenommen. Die Transaktion, genehmigt am 14. August 2025, umfasst ein PIPE-Angebot, das zusammen mit Treuhandmitteln über 11,5 Millionen US-Dollar für die künftige Geschäftstätigkeit bereitstellen wird.
Unter der Leitung des Vorsitzenden Dr. Ethan Shen konzentriert sich YD Bio auf drei Kernbereiche: die krebsdiagnostik auf Basis der DNA-Methylierung in Partnerschaft mit EG BioMed, ophthalmologische Therapien, die mit 3D Global Biotech entwickelt werden, und Unterstützungsleistungen für klinische Studien. Das Krebsdiagnostik-Portfolio umfasst einen Screening-Test für Bauchspeicheldrüsenkrebs und einen bald erscheinenden Test zur Überwachung von Brustkrebsrückfällen, während das Ophthalmologieprogramm plant, 2027 mit Studien zu exosombasierten Behandlungen zu beginnen.
- Secured over $11.5 million in funding through PIPE offering and trust funds
- Multi-decade exclusive licensing agreements provide first-mover advantage
- Existing pancreatic cancer screening test already available as LDT
- Diversified portfolio across diagnostics, therapeutics, and clinical services
- Ophthalmology clinical trials not starting until 2027
- Heavy reliance on partnerships for core technologies
- Limited cash position relative to typical biotech companies
Insights
YD Bio successfully completed its SPAC merger, secured $11.5M in funding, and commenced Nasdaq trading, positioning it for growth in cancer diagnostics and ophthalmology.
YD Bio Limited has successfully completed its business combination with Breeze Holdings Acquisition Corp and commenced trading on the Nasdaq Global Market under ticker symbols "YDES" and "YDESW" for shares and warrants respectively. The transaction, approved by Breeze shareholders on August 14, 2025, represents a pivotal milestone in the company's evolution from a clinical trial supplier to a publicly-traded biotechnology innovator.
The company secured more than
The company's most advanced program focuses on DNA methylation-based cancer detection technology through licensing agreements with EG BioMed. Their pancreatic cancer screening test is already available as a laboratory-developed test (LDT), with a breast cancer recurrence monitoring test expected to launch later this year. These tests address critical needs in cancer management, particularly for pancreatic cancer, which typically has poor survival rates due to late detection.
In ophthalmology, YD Bio is developing stem cell and exosome-based therapies for ocular diseases through its partnership with 3D Global Biotech. The company has secured IRB approval for specimen collection and plans to initiate clinical trials for exosome-based contact lenses and artificial tears in 2027 - though this represents a longer-term value proposition with revenue potential several years away.
The company also maintains a clinical trial services business, leveraging established relationships with pharmaceutical companies. This segment likely provides more immediate, stable revenue while the diagnostic and therapeutic programs advance.
The successful SPAC merger and public listing give YD Bio enhanced access to capital markets, increased visibility, and potential for strategic partnerships - all critical factors for emerging biotech companies. However, investors should note that early-stage biotech companies typically face significant development, regulatory, and commercialization challenges before achieving profitability.
- Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market Expansion
- Trading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the Nasdaq Global Market on August 29, 2025, under the ticker symbols "YDES" and "YDESW"
The Company also announced that the previously announced PIPE offering closed, in full, contemporaneously with the closing of the business combination. The proceeds of the PIPE offering together with the cash released to the Company from the trust for the benefit of the former Breeze shareholders, after satisfaction of all business combination closing-related expenses, is expected to yield more than
The Business Combination and the PIPE closing mark a significant step in the Company's evolution, positioning YD Bio Ltd as an emerging leader in the biotech industry with strong growth potential across multiple fast-growing healthcare markets. By entering the public markets, YD Bio Ltd is poised to accelerate innovation, scale production, and drive the development and commercialization of groundbreaking technologies.
YD Bio Ltd's business model centers on partnerships with biopharmaceutical companies to transform innovative technologies into commercially viable drugs and cancer detection diagnostics. Led by Chairman Dr. Ethan Shen, a biomedical expert with over 30 years of experience, the Company is focused on advancing a diversified portfolio of innovative healthcare solutions across oncology diagnostics, regenerative medicine, and clinical trial support. The Company's core programs include:
- Blood-Based Cancer Detection: Through exclusive licensing agreements with its partner EG BioMed, the Company is developing proprietary DNA methylation-based detection technology for a range of cancers. This includes a screening test for the early detection of pancreatic cancer, which is available as a laboratory-developed test (LDT) through EG BioMed's CLIA-certified laboratory, and a monitoring test for recurrent breast cancer, expected to launch as an LDT later this year.
- Stem Cell- and Exosome-Based Ophthalmology Therapies: In partnership with 3D Global Biotech, the Company is advancing corneal stem cell and exosome technologies for the treatment of ocular diseases such as dry eye syndrome, glaucoma, and corneal injury. Clinical development efforts are underway, with Institutional Review Board (IRB)-approved specimen collection and plans to initiate trials evaluating exosome-based contact lenses and artificial tears in 2027.
- Clinical Trial and Ancillary Services: The Company has served as a trusted supplier of investigational drugs and ancillary materials to global pharmaceutical companies, supporting clinical development and post-launch commercialization.
The Company's multi-decade exclusive licensing agreements, together with its proprietary patented technologies, provide the Company with a significant first-mover advantage across its clinical markets.
"Today is an incredibly proud moment and a major milestone for our company, our employees and our shareholders, as we begin our journey as a publicly traded company," said Dr. Ethan Shen, Chairman of the Board and Chief Executive Officer of YD Bio Ltd. "Since our founding in 2013, YD Bio has evolved from a supplier of clinical trial drugs and health supplements into a dynamic innovator in diagnostics and therapeutics. From pioneering exosome technologies to advancing early cancer detection, our progress reflects years of dedication and transformation. Becoming a publicly traded Nasdaq-listed company enables us to accelerate our mission of delivering innovative solutions that improve lives and advance global health. We are profoundly grateful to the patients who participate in our trials, our dedicated team members, and our investors. We believe this achievement represents the next step in advancing our programs and products, redefining the future of healthcare, and bringing life-changing solutions to patients who need them."
Advisors
ArentFox Schiff LLP and Ogier acted as legal advisors to the Company. I-Bankers Securities, Inc. acted as financial advisor to Breeze. Woolery & Co. PLLC acted as legal advisor to Breeze.
About YD Bio Limited
YD Bio Limited is a biotechnology company focused on advancing clinical trials, new drug development, cancer prevention diagnostics, stem cell and exosome therapies with the potential to transform the treatment of diseases with high unmet medical need. The Company is committed to improving patient outcomes through scientific innovation and precision medicine. In addition to its R&D efforts, YD Bio Limited is a recognized supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. For more information, please visit the Company's website: www.ydesgroup.com
About Breeze Holdings Acquisition Corp.
Breeze Holdings is a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses or entities.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements, including, but not limited to, YD Bio's business plan and outlook. These forward-looking statements involve known and unknown risks and uncertainties and are based on YD Bio's current expectations and projections about future events that YD Bio believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. YD Bio undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although YD Bio believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and YD Bio cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in YD Bio's registration statement and other filings with the
For investor and media inquiries, please contact:
YD Bio Limited
Investor Relations
Email: investor@ydesgroup.com
Jackson Lin
LLYC US
Phone: +1 (646) 717-4593
Email: jian.lin@llyc.global
View original content to download multimedia:https://www.prnewswire.com/news-releases/yd-bio-limited-announces-closing-of-business-combination-and-listing-on-the-nasdaq-global-market-302541806.html
SOURCE YD Bio Limited
FAQ
What is YD Bio's (YDES) stock symbol and when did it start trading on Nasdaq?
How much funding did YD Bio (YDES) secure from its business combination?
What are YD Bio's (YDES) main business segments?
When will YD Bio (YDES) begin clinical trials for its ophthalmology treatments?
What cancer detection products does YD Bio (YDES) currently offer?
